BenQ Medical Technology (4116) — Cash Flow Reinvestment Rate

Latest as of June 2025: 0.42x

BenQ Medical Technology (4116) has a Cash Flow Reinvestment Rate of 0.42x as of June 2025, reinvesting NT$76.10 Million (capex NT$14.79 Million plus investments NT$-61.31 Million) from operating cash flow of NT$179.07 Million. Explore BenQ Medical Technology capital spending ratio to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

0.42x
(Capex + Investments) / Operating CF

Total Reinvested

NT$76.10 Million
Capex + Investments

Operating Cash Flow

NT$179.07 Million
TWD

Capital Expenditures

NT$14.79 Million
TWD

BenQ Medical Technology Cash Flow Reinvestment Rate (2017–2024)

Historical reinvestment intensity for BenQ Medical Technology across 8 annual periods. Also explore BenQ Medical Technology asset portfolio for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for BenQ Medical Technology (2017–2024)

Year-by-year capital reinvestment analysis for BenQ Medical Technology. For live market cap and broader valuation context, see BenQ Medical Technology market capitalisation.

Year Reinvestment Rate Total Reinvested (TWD) Operating CF Capex YoY Change
2024 0.88x NT$195.80 Million NT$222.22 Million NT$175.48 Million ▲ +45.5%
2023 0.61x NT$267.96 Million NT$442.35 Million NT$139.28 Million ▲ +39.9%
2022 0.43x NT$164.04 Million NT$378.77 Million NT$60.05 Million ▼ -45.2%
2021 0.79x NT$95.91 Million NT$121.35 Million NT$32.92 Million ▲ +54.4%
2020 0.51x NT$77.53 Million NT$151.48 Million NT$42.37 Million ▲ +205.9%
2019 0.17x NT$28.32 Million NT$169.23 Million NT$21.15 Million ▼ -57.1%
2018 0.39x NT$49.21 Million NT$126.10 Million NT$31.36 Million ▼ -77.9%
2017 1.77x NT$128.91 Million NT$72.97 Million NT$112.31 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow